[
1. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011 Sep 8;6:60.10.1186/1750-1172-6-60319867421902819
]Search in Google Scholar
[
2. Feitz WJC, van de Kar NCAJ, Orth-Höller D, et al. The genetics of atypical hemolytic uremic syndrome. Med Genet. 2018;30(4):400-409.10.1007/s11825-018-0216-0640438930930551
]Search in Google Scholar
[
3. Józsi M, Licht C, Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2008 Feb 1;111(3):1512-4.10.1182/blood-2007-09-10987618006700
]Search in Google Scholar
[
4. Moore I, Strain L, Pappworth I, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010 Jan 14;115(2):379-87.10.1182/blood-2009-05-221549282985919861685
]Search in Google Scholar
[
5. Hofer J, Janecke AR, Zimmerhackl LB, et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2013 Mar;8(3):407-15.10.2215/CJN.01260212358696023243267
]Search in Google Scholar
[
6. Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005 Feb;16(2):555-63.10.1681/ASN.200405038015590760
]Search in Google Scholar
[
7. Dragon-Durey MA, Sethi SK, Bagga A, et al. Clinical features of anti-factor H autoanti-body-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010 Dec;21(12):2180-7.10.1681/ASN.2010030315301403121051740
]Search in Google Scholar
[
8. Moore I, Strain L, Pappworth I, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010 Jan 14;115(2):379-87.10.1182/blood-2009-05-221549
]Search in Google Scholar
[
9. Sana G, Dragon-Durey MA, Charbit M, et al. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol. 2014 Jan;29(1):75-83.10.1007/s00467-013-2558-923868108
]Search in Google Scholar
[
10. Boyer O, Balzamo E, Charbit M, et al. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am J Kidney Dis. 2010 May;55(5):923-7.10.1053/j.ajkd.2009.12.02620202729
]Search in Google Scholar
[
11. Khandelwal P, Sinha A, Hari P, Bagga A. Plasma exchanges and immunosuppression for anti-complement factor H associated hemolytic uremic syndrome. Indian Pediatr. 2014 Oct;51(10):833-5.
]Search in Google Scholar
[
12. Skerka C, Zipfel PF, Müller D, et al. The autoimmune disease DEAP-hemolytic uremic syndrome. Semin Thromb Hemost. 2010 Sep;36(6):625-32.10.1055/s-0030-126288420865639
]Search in Google Scholar
[
13. Bagga A, Khandelwal P, Mishra K, et al. Hemolytic uremic syndrome in a developing country: Consensus guidelines. Pediatr Nephrol. 2019 Aug;34(8):1465-1482.10.1007/s00467-019-04233-730989342
]Search in Google Scholar
[
14. Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016 Jan;31(1):15-39.10.1007/s00467-015-3076-825859752
]Search in Google Scholar
[
15. Hofer J, Riedl Khursigara M, Perl M, et al. Early relapse rate determines further relapse risk: results of a 5-year follow-up study on pediatric CFH-Ab HUS. Pediatr Nephrol. 2021 Apr;36(4):917-925.10.1007/s00467-020-04751-9791023133025207
]Search in Google Scholar
